Achilles Therapeutics PLC (ACHL) FinancialsACHLAchilles Therapeutics PLC

Evaluating the bottom line, Achilles Therapeutics PLC maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -52.12%, provide a clear picture of how effectively ACHL converts its operational activities into shareholder value.

In the context of the broader market, ACHL competes directly with industry leaders such as CANF and APLT. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ACHL's gross margin of N/A stands against CANF's 100.00% and APLT's 100.00%. Such benchmarking helps identify whether Achilles Therapeutics PLC is trading at a premium or discount relative to its financial performance.